E1-I: Final Phase IIa data

In a double-blind, placebo-controlled, U.S. Phase IIa trial in 30 Type II diabetics with baseline HbA1c levels of >=7%, mean HbA1c levels were reduced by 0.94-1.21% from baseline at 2-6 months post-tr...